查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球细胞系开发市场 2023-2030
市场调查报告书
商品编码
1380398

全球细胞系开发市场 2023-2030

Global Cell Line Development Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

预计全球细胞系开发市场在预测期内（2023-2030）将以 9.6% 的CAGR成长。细胞系开发是生物技术和药物研究的关键过程，旨在创建稳定且高产量的细胞係以生产治疗性蛋白质、抗体、疫苗和其他生物製药。第一步涉及选择合适的宿主细胞系，通常源自哺乳动物、昆虫或微生物来源，这取决于产品的特定要求。

细分市场前景

全球细胞系开发市场按产品类型、来源类型、最终用户和细胞系进行细分。根据产品类型，市场分为试剂和介质、设备和配件以及消耗品。根据来源类型，市场分为哺乳动物和非哺乳动物。根据最终用户，市场细分为生物製药和生物技术公司、合约研究组织以及学术和研究机构。根据细胞系，市场分为重组细胞、杂交瘤、连续细胞和原代细胞。在细胞系中，由于对治疗癌症和自体免疫疾病的生物製剂的需求不断增长，预计重组子细分市场将占据相当大的市场份额。

预计哺乳动物细分市场将在全球细胞系开发市场中占据相当大的份额

在来源类型中，哺乳动物细分市场预计将在全球细胞系开发市场中占据相当大的份额。这种分段增长归因于多种因素，例如哺乳动物细胞来源被用于生产单株抗体。这些细胞系产生复杂的蛋白质，让人想起人体中的蛋白质，有助于创建定製药物。此外，人体组织和其他生物成分可以轻鬆适应哺乳动物细胞系，进而降低感染风险。例如，2023 年6 月，Synthego 宣布与全球首屈一指的非营利生物材料和标准资源中心ATCC 建立突破性合作伙伴关係，为研究人员提供大量用于基因编辑应用的哺乳动物和小鼠细胞系，包括Express Cell池可提高获得结果的速度。该联盟汇集了其在基因组工程方面的专业知识以及 ATCC 作为经过验证的生物材料和标准的值得信赖的提供者的声誉。

区域展望

全球细胞系开发市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于医疗基础设施的改善以及该地区政府的有利倡议，预计亚太地区将在全球市场中占据显着份额。

北美地区预计全球细胞系开发市场将以显着的复合CAGR成长

在所有地区中，北美地区预计在预测期内将以相当大的CAGR成长。区域成长归因于医疗基础设施的改善以及市场参与者为更好地研究和产品开发而增加的策略性倡议。例如，2023 年 9 月，Lineage Cell Therapeutics, Inc. 宣布根据该公司与 Eterna Therapeutics Inc. 的独家选择权和许可协议启动某些开发活动，以产生新型低免疫诱导多能干细胞 (iPSC) 系。这是2023 年2 月宣布的策略合作的下一步，根据该合作，Eterna 正在开发创新的工程低免疫iPSC 系，Lineage 将评估其分化为中枢神经系统(CNS) 疾病和其他神经病学适应症的细胞移植产品候选者的能力。自从早些时候宣布此项交易以来，Lineage 已与美国和国外领先的神经病学专家小组评估了其发展策略。经过这些和其他讨论以及对竞争格局的评估，Lineage 最终确定了为 Eterna 开发的初始细胞系选择特定基因编辑。这些编辑包括定向删除 B2M 基因，旨在透过抑制 CD8+ T 细胞的排斥来降低源自该品系的候选产品的免疫原性； HLA-E 基因的标靶插入，旨在过度表达 HLA-E 并防止同种异体 NK 细胞反应，以及第三次未公开的编辑，旨在赋予临床差异化和适用适应症的竞争优势。 Lineage 预计这些编辑将扩大编辑细胞系的整体效用，包括非免疫特权或非人类白血球抗原 (HLA) 匹配的适应症，并将进一步将该细胞系与竞争对手目前使用的其他细胞系区分开来。

市场参与者展望

服务于细胞系开发市场的主要公司包括： Advanced Instruments、Berkeley Lights、Boehringer Ingelheim International GmbH、Creative BioLabs.、Danaher、Fujifilm Holdings Corp、Horizo​​​​n Discovery Ltd.、JSR Corp、Lonza、Merck KGaA Corning Inc.等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2019 年 4 月，细胞系开发 (CLD) 成像仪器生产商 Solentim 与生长促进非动物细胞培养试剂供应商 SAL Scientific 宣布建立新的策略合作伙伴关係。此次合作将透过提供可显着改善细胞生长的新型补充剂来进一步优化 CLD 工作流程。 Solentim 将担任 SAL Scientific 'Insti' 产品系列的独家经销商。在化学成分明确、不含动物成分的培养基中生长的细胞可能容易受到生长和活力受损的影响，尤其是在受到压力时。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 在全球细胞系开发市场运营的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Corning Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • GE Healthcare
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Thermo Fisher Scientific Inc
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按产品类型分類的全球细胞系开发市场
    • 试剂和介质
    • 装置
    • 配件及消耗品
  • 按来源类型分類的全球细胞系开发市场
    • 哺乳动物
    • 非哺乳动物
  • 按最终用户分類的全球细胞系开发市场
    • 生物製药和生物技术公司
    • 学术界及研究机构
    • 合约研究组织
  • 按细胞系分類的全球细胞系开发市场
    • 重组
    • 杂交瘤
    • 连续的
    • 基本的

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Advanced Instruments
  • Berkeley Lights, Inc.
  • Boehringer Ingelheim International GmbH
  • Creative BioLabs.
  • Danaher Corp.
  • Fujifilm Holdings Corp
  • Horizon Discovery Ltd.
  • JSR Corp.
  • Lonza Group Ltd
  • Merck KGaA Corning Inc.
  • Rentschler Biopharma SE
  • Sartorius AG
  • Selexis SA
  • Sigma-Aldrich Corp
  • WuXi PharmaTech
Product Code: OMR2027859

Title: Global Cell Line Development Market Size, Share & Trends Analysis Report by Product Type (Reagent and Media, Equipment and Accessories and Consumables), by Source Type (Mammalian and Non-mammalian), by End User (Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes) and by Cell Line (Recombinant, Hybridomas, Continuous and Primary),Forecast Period (2023-2030).

The global Cell Line Development market is anticipated to grow at a CAGR of 9.6% during the Forecast Period (2023-2030). Cell line development is a critical process in biotechnology and pharmaceutical research, aimed at creating stable and high-yielding cell lines to produce therapeutic proteins, antibodies, vaccines, and other biopharmaceuticals. The initial step involves choosing a suitable host cell line, often derived from mammalian, insect, or microbial sources, depending on the specific requirements of the product.

Segmental Outlook

The global Cell Line Development market is segmented on the product type, Source type, End user, and cell line. Based on the product type, the market is sub-segmented into Reagent and Media, Equipment and Accessories and Consumables. Based on source type, the market is sub-segmented into Mammalian and Non-mammalian. Based on the end user, the market is sub-segmented into Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes. And based on cell line, the market is segmented into Recombinant, Hybridomas, Continuous and Primary. Among the cell line, the Recombinant sub-segment is anticipated to hold a considerable share of the market, owing to rising demand for biologics to treat cancer and autoimmune illnesses.

The Mammalian Sub-Segment is Anticipated to Hold a Considerable Share of the Global Cell Line Development Market

Among the Source Type, the Mammalian sub-segment is expected to hold a considerable share of the global Cell Line Development market. This segmental growth is attributed to several factors such as, mammalian cell sources are being used to create monoclonal antibodies. These cell lines produce intricate proteins that are reminiscent of those in the human body, aiding in the creation of customized medications. Additionally, human tissues and other biological components can easily adapt to mammalian cell lines, lowering the risk of infection. For instance, In June 2023, Synthego, announced a groundbreaking partnership with ATCC, the premier non-profit global biological materials and standards resource center, to provide researchers with an extensive collection of mammalian and mouse cell lines for gene editing applications, including Express Cell Pools to increase speed to results. This alliance brings together its expertise in genome engineering and ATCC's renowned reputation as a trusted provider of authenticated biological materials and standards.

Regional Outlook

The global Cell Line Development market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to improving healthcare infrastructure, and favorable initiatives by government in the region.

The North America Region is Expected to Grow at a Significant CAGR in the Global Cell Line Development Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to improving medical infrastructure and increasing strategic initiatives by market players for better research and product development in the regions. For instance, in September 2023, Lineage Cell Therapeutics, Inc., announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company's exclusive option and license agreement with Eterna Therapeutics Inc. This marks the next step under the strategic collaboration announced in February 2023, under which Eterna is developing innovative engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system (CNS) diseases and other neurology indications. Since announcing the deal earlier, Lineage has evaluated its development strategy with a group of leading neurology experts in the US and abroad. As a result of these and other discussions, and an assessment of the competitive landscape, Lineage finalized its selection of specific gene edits for the initial cell lines to be developed by Eterna. The edits include the targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells; the targeted insertion of the HLA-E gene, designed to overexpress HLA-E and prevent the allogeneic NK cell response, and a third undisclosed edit intended to confer clinical differentiation and a competitive advantage in the applicable indications. Lineage expects that these edits would expand the edited cell lines' overall utility, including for non-immune privileged or non-human leukocyte antigen (HLA) matched indications and will further differentiate the cell line from others currently in use by competitors.

Market Players Outlook

The major companies serving the Cell Line Development market include: Advanced Instruments, Berkeley Lights, Boehringer Ingelheim International GmbH, Creative BioLabs., Danaher, Fujifilm Holdings Corp, Horizon Discovery Ltd., JSR Corp, Lonza, Merck KGaA Corning Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2019, Solentim, the cell line development (CLD) imaging instrumentation producer, and SAL Scientific, a provider of growth-enhancing animal-free cell culture reagents, announced a new strategic partnership. The collaboration will further optimise CLD workflow by supplying novel supplements which substantially improve cell growth. Solentim will act as the exclusive distributor for the SAL Scientific 'Insti' product range. Cells grown in chemically defined, animal component-free media can be susceptible to impaired growth and viability, especially when subjected to stress.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Cell Line Development market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Corning Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. GE Healthcare
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cell line development Market by Product Type
    • 4.1.1. Reagent and Media
    • 4.1.2. Equipment
    • 4.1.3. Accessories and Consumables
  • 4.2. Global Cell line development Market by Source Type
    • 4.2.1. Mammalian
    • 4.2.2. Non-mammalian
  • 4.3. Global Cell line development Market by End-User
    • 4.3.1. Biopharmaceutical and Biotechnology companies
    • 4.3.2. Academics and Research Institutes
    • 4.3.3. Contract Research Organizations
  • 4.4. Global Cell line development Market by Cell Line
    • 4.4.1. Recombinant
    • 4.4.2. Hybridomas
    • 4.4.3. Continuous
    • 4.4.4. Primary

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advanced Instruments
  • 6.2. Berkeley Lights, Inc.
  • 6.3. Boehringer Ingelheim International GmbH
  • 6.4. Creative BioLabs.
  • 6.5. Danaher Corp.
  • 6.6. Fujifilm Holdings Corp
  • 6.7. Horizon Discovery Ltd.
  • 6.8. JSR Corp.
  • 6.9. Lonza Group Ltd
  • 6.10. Merck KGaA Corning Inc.
  • 6.11. Rentschler Biopharma SE
  • 6.12. Sartorius AG
  • 6.13. Selexis SA
  • 6.14. Sigma-Aldrich Corp
  • 6.15. WuXi PharmaTech

LIST OF TABLES

  • 1. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL REAGENT AND MEDIA FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL EQUIPMENT FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ACCESSORIES AND CONSUMABLES FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL MAMMALIAN IN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 7. GLOBAL NON-MAMMALIAN IN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 8. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 9. GLOBAL CELL LINE DEVELOPMENT FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CELL LINE DEVELOPMENT FOR ACADEMICS AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CELL LINE DEVELOPMENT FOR CONTRACT RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 13. GLOBAL RECOMBINANT CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL HYBRIDOMAS CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CONTINUOUS CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL PRIMARY CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 26. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 27. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL REAGENT AND MEDIA FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL EQUIPMENT FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ACCESSORIES AND CONSUMABLES FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY SOURCE TYPE, 2022 VS 2030 (%)
  • 6. GLOBAL MAMMALIAN IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL NON-MAMMALIAN IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 9. GLOBAL CELL LINE DEVELOPMENT FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CELL LINE DEVELOPMENT FOR ACADEMICS AND RESEARCH INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CELL LINE DEVELOPMENT FOR CONTRACT RESEARCH ORGANIZATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY CELL LINES, 2022 VS 2030 (%)
  • 13. GLOBAL RECOMBINANT IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL HYBRIDOMAS CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CONTINUOUS CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PRIMARY CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)